Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Biochemical Characteristics and Allergenic activity of Common Fungus Allergens.

Lisha L, Kai G, Guo ZS.

Curr Protein Pept Sci. 2019 Jul 12. doi: 10.2174/1389203720666190712121243. [Epub ahead of print]

PMID:
31309887
2.

A cautionary note on the selectivity of oncolytic poxviruses.

Tang B, Guo ZS, Bartlett DL, Liu J, McFadden G, Shisler JL, Roy EJ.

Oncolytic Virother. 2019 Feb 11;8:3-8. doi: 10.2147/OV.S189832. eCollection 2019.

3.

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.

Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL.

J Immunother Cancer. 2019 Jan 9;7(1):6. doi: 10.1186/s40425-018-0495-7. Review.

4.

The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer).

Guo ZS.

BMC Cancer. 2018 Nov 12;18(1):1086. doi: 10.1186/s12885-018-5020-3. No abstract available.

5.

Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2.

Liu Z, Ge Y, Wang H, Ma C, Feist M, Ju S, Guo ZS, Bartlett DL.

Nat Commun. 2018 Nov 8;9(1):4682. doi: 10.1038/s41467-018-06954-z.

6.

Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.

Kowalsky SJ, Liu Z, Feist M, Berkey SE, Ma C, Ravindranathan R, Dai E, Roy EJ, Guo ZS, Bartlett DL.

Mol Ther. 2018 Oct 3;26(10):2476-2486. doi: 10.1016/j.ymthe.2018.07.013. Epub 2018 Jul 17.

7.

PARK7 modulates autophagic proteolysis through binding to the N-terminally arginylated form of the molecular chaperone HSPA5.

Lee DH, Kim D, Kim ST, Jeong S, Kim JL, Shim SM, Heo AJ, Song X, Guo ZS, Bartlett DL, Oh SC, Lee J, Saito Y, Kim BY, Kwon YT, Lee YJ.

Autophagy. 2018;14(11):1870-1885. doi: 10.1080/15548627.2018.1491212. Epub 2018 Jul 23.

8.

Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei.

Dilly AK, Honick BD, Lee YJ, Guo ZS, Zeh HJ, Bartlett DL, Choudry HA.

Oncotarget. 2017 Nov 6;8(63):106888-106900. doi: 10.18632/oncotarget.22455. eCollection 2017 Dec 5.

9.

Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus.

Guo ZS, Liu Z, Sathaiah M, Wang J, Ravindranathan R, Kim E, Huang S, Kenniston TW, Bell JC, Zeh HJ 3rd, Butterfield LH, Gambotto A, Bartlett DL.

Mol Ther Methods Clin Dev. 2017 Sep 30;7:112-122. doi: 10.1016/j.omtm.2017.09.007. eCollection 2017 Dec 15.

10.

Analysis of the Mitochondrial 4977 Bp Deletion in Patients with Hepatocellular Carcinoma.

Guo ZS, Jin CL, Yao ZJ, Wang YM, Xu BT.

Balkan J Med Genet. 2017 Jun 30;20(1):81-86. doi: 10.1515/bjmg-2017-0006. eCollection 2017 Jun 30.

11.

The Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells.

Wu S, Zhu W, Peng Y, Wang L, Hong Y, Huang L, Dong D, Xie J, Merchen T, Kruse E, Guo ZS, Bartlett D, Fu N, He Y.

Cancer Immunol Res. 2017 Oct;5(10):908-919. doi: 10.1158/2326-6066.CIR-17-0016. Epub 2017 Aug 29.

12.

Editorial of the Special Issue: Oncolytic Viruses as a Novel Form of Immunotherapy for Cancer.

Guo ZS, Bartlett DL.

Biomedicines. 2017 Aug 24;5(3). pii: E52. doi: 10.3390/biomedicines5030052.

13.

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.

Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, Storkus WJ, Bartlett DL.

Front Immunol. 2017 May 15;8:555. doi: 10.3389/fimmu.2017.00555. eCollection 2017. Review.

14.

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.

Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL.

Nat Commun. 2017 Mar 27;8:14754. doi: 10.1038/ncomms14754.

15.

Synergistic Effect of Mesoporous Silica and Hydroxyapatite in Loaded Poly(DL-lactic-co-glycolic acid) Microspheres on the Regeneration of Bone Defects.

He S, Lin KF, Fan JJ, Hu G, Dong X, Zhao YN, Song Y, Guo ZS, Bi L, Liu J.

Biomed Res Int. 2016;2016:9824827. doi: 10.1155/2016/9824827. Epub 2016 Aug 29.

16.

Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.

Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O'Malley ME, Jones HL, Moon A, McCart JA, Shuai Y, Zeh HJ, Bartlett DL.

Mol Ther. 2016 Aug;24(8):1492-501. doi: 10.1038/mt.2016.101. Epub 2016 May 16.

17.

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.

Liu Z, Ravindranathan R, Li J, Kalinski P, Guo ZS, Bartlett DL.

Oncoimmunology. 2015 Oct 29;5(3):e1091554. eCollection 2016 Mar.

18.

Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer.

Francis L, Guo ZS, Liu Z, Ravindranathan R, Urban JA, Sathaiah M, Magge D, Kalinski P, Bartlett DL.

Oncotarget. 2016 Apr 19;7(16):22174-85. doi: 10.18632/oncotarget.7907.

19.

Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.

Matveeva OV, Guo ZS, Shabalina SA, Chumakov PM.

Mol Ther Oncolytics. 2015;2. pii: 15011. Epub 2015 Jul 22.

20.

Oncolysis by paramyxoviruses: preclinical and clinical studies.

Matveeva OV, Guo ZS, Senin VM, Senina AV, Shabalina SA, Chumakov PM.

Mol Ther Oncolytics. 2015;2. pii: 150017. Epub 2015 Oct 21.

21.

Targeting hypoxia-mediated mucin 2 production as a therapeutic strategy for mucinous tumors.

Dilly AK, Lee YJ, Zeh HJ, Guo ZS, Bartlett DL, Choudry HA.

Transl Res. 2016 Mar;169:19-30.e1. doi: 10.1016/j.trsl.2015.10.006. Epub 2015 Oct 31.

PMID:
26589109
22.

TRAIL-Induced Caspase Activation Is a Prerequisite for Activation of the Endoplasmic Reticulum Stress-Induced Signal Transduction Pathways.

Lee DH, Sung KS, Guo ZS, Kwon WT, Bartlett DL, Oh SC, Kwon YT, Lee YJ.

J Cell Biochem. 2016 May;117(5):1078-91. doi: 10.1002/jcb.25289. Epub 2016 Feb 5.

PMID:
26212606
23.

Effects of graphene modification on the bioactivation of polyethylene-terephthalate-based artificial ligaments.

Wang CH, Guo ZS, Pang F, Zhang LY, Yan M, Yan JH, Li KW, Li XJ, Li Y, Bi L, Han YS.

ACS Appl Mater Interfaces. 2015 Jul 22;7(28):15263-76. doi: 10.1021/acsami.5b02893. Epub 2015 Jul 7.

PMID:
26111253
24.

Effects of Artificial Ligaments with Different Porous Structures on the Migration of BMSCs.

Wang CH, Hou W, Yan M, Guo ZS, Wu Q, Bi L, Han YS.

Stem Cells Int. 2015;2015:702381. doi: 10.1155/2015/702381. Epub 2015 May 28.

25.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

26.

Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth.

Dilly AK, Song X, Zeh HJ, Guo ZS, Lee YJ, Bartlett DL, Choudry HA.

Transl Res. 2015 Oct;166(4):344-54. doi: 10.1016/j.trsl.2015.03.004. Epub 2015 Mar 28.

PMID:
25890193
27.

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O'Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbach CJ, Kirn DH, Bartlett DL.

Mol Ther. 2015 Jan;23(1):202-14. doi: 10.1038/mt.2014.194. Epub 2014 Oct 8.

28.

Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land.

Guo ZS, Bartlett DL.

Cancer Gene Ther. 2014 Jul;21(7):261-3. doi: 10.1038/cgt.2014.31. No abstract available.

29.

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.

Guo ZS, Liu Z, Bartlett DL.

Front Oncol. 2014 Apr 10;4:74. doi: 10.3389/fonc.2014.00074. eCollection 2014. Review.

30.

[Atmospheric emission of PCDD/Fs from modern dry processing cement kilns with preheating in the southwest area, China].

Zhang XL, Lu Y, Jian C, Guo ZS, Zhu MJ, Deng L, Sun J, Zhang Q.

Huan Jing Ke Xue. 2014 Jan;35(1):35-40. Chinese.

PMID:
24720182
31.

[Atmospheric emission of PCDD/Fs from secondary aluminum metallurgy industry in the southwest area, China].

Lu Y, Zhang XL, Guo ZS, Jian C, Zhu MJ, Deng L, Sun J, Zhang Q.

Huan Jing Ke Xue. 2014 Jan;35(1):30-4. Chinese.

PMID:
24720181
32.

[Concentrations of PCDD/Fs in the atmosphere of Chongqing City and its seasonal variation].

Zhang XL, Lu Y, Zhu MJ, Jian C, Guo ZS, Deng L, Sun J, Zhang Q, Luo CH.

Huan Jing Ke Xue. 2014 Jan;35(1):22-9. Chinese.

PMID:
24720180
33.

T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.

Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT.

Mol Ther. 2014 Jan;22(1):102-11. doi: 10.1038/mt.2013.240. Epub 2013 Oct 17.

34.

Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma.

Hong Y, Peng Y, Guo ZS, Guevara-Patino J, Pang J, Butterfield LH, Mivechi NF, Munn DH, Bartlett DL, He Y.

Hepatology. 2014 Apr;59(4):1448-58. doi: 10.1002/hep.26893. Epub 2014 Feb 18.

35.

Oncolytic viruses as therapeutic cancer vaccines.

Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS.

Mol Cancer. 2013 Sep 11;12(1):103. doi: 10.1186/1476-4598-12-103. Review.

36.

Inhibitors of C5 complement enhance vaccinia virus oncolysis.

Magge D, Guo ZS, O'Malley ME, Francis L, Ravindranathan R, Bartlett DL.

Cancer Gene Ther. 2013 Jun;20(6):342-50. doi: 10.1038/cgt.2013.26. Epub 2013 May 10.

37.

Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.

Xiao H, Peng Y, Hong Y, Huang L, Guo ZS, Bartlett DL, Fu N, Munn DH, Mellor A, He Y.

J Immunol. 2013 Jun 1;190(11):5866-73. doi: 10.4049/jimmunol.1203470. Epub 2013 Apr 22.

38.

A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.

Thirunavukarasu P, Sathaiah M, Gorry MC, O'Malley ME, Ravindranathan R, Austin F, Thorne SH, Guo ZS, Bartlett DL.

Mol Ther. 2013 May;21(5):1024-33. doi: 10.1038/mt.2013.27. Epub 2013 Feb 26.

39.

Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Guo ZS, Liu Z, Bartlett DL, Tang D, Lotze MT.

Am J Cancer Res. 2013;3(1):1-20. Epub 2013 Jan 18.

40.

Mucin as a therapeutic target in pseudomyxoma peritonei.

Choudry HA, O'Malley ME, Guo ZS, Zeh HJ, Bartlett DL.

J Surg Oncol. 2012 Dec;106(7):911-7. doi: 10.1002/jso.23146. Epub 2012 May 14. Review.

PMID:
22585683
41.

Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.

John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL, Smyth MJ, Kershaw MH, Darcy PK.

Cancer Res. 2012 Apr 1;72(7):1651-60. doi: 10.1158/0008-5472.CAN-11-2788. Epub 2012 Feb 7.

42.

Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer.

Sathaiah M, Thirunavukkarasu P, O'Malley ME, Kavanagh MA, Ravindranathan R, Austin F, Guo ZS, Bartlett DL.

Cancer Gene Ther. 2012 Mar;19(3):192-201. doi: 10.1038/cgt.2011.77. Epub 2011 Nov 25.

43.

Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma.

Xiao H, Peng Y, Hong Y, Liu Y, Guo ZS, Bartlett DL, Fu N, He Y.

J Immunol. 2011 Aug 15;187(4):1788-96. doi: 10.4049/jimmunol.1101138. Epub 2011 Jul 11.

44.

Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth.

Li Q, O'Malley ME, Bartlett DL, Guo ZS.

Mol Cancer. 2011 May 24;10:63. doi: 10.1186/1476-4598-10-63.

45.

Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis.

Feng B, Eknoyan G, Guo ZS, Jadoul M, Rao HY, Zhang W, Wei L.

Nephrol Dial Transplant. 2012 Feb;27(2):640-6. doi: 10.1093/ndt/gfr236. Epub 2011 May 10. Review.

PMID:
21558431
46.

[Soil water resource use limit in semi-arid loess hilly area].

Guo ZS.

Ying Yong Sheng Tai Xue Bao. 2010 Dec;21(12):3029-35. Chinese.

PMID:
21442986
47.

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL.

Mol Ther. 2011 Apr;19(4):650-7. doi: 10.1038/mt.2010.312. Epub 2011 Jan 25.

48.

Epigenetic drugs for cancer treatment and prevention: mechanisms of action.

Yu XD, Guo ZS.

Biomol Concepts. 2010 Oct 1;1(3-4):239-51. doi: 10.1515/bmc.2010.020.

PMID:
25962000
49.

The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.

Guo ZS, Parimi V, O'Malley ME, Thirunavukarasu P, Sathaiah M, Austin F, Bartlett DL.

Gene Ther. 2010 Dec;17(12):1465-75. doi: 10.1038/gt.2010.104. Epub 2010 Aug 12.

50.

TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer.

Ziauddin MF, Guo ZS, O'Malley ME, Austin F, Popovic PJ, Kavanagh MA, Li J, Sathaiah M, Thirunavukarasu P, Fang B, Lee YJ, Bartlett DL.

Gene Ther. 2010 Apr;17(4):550-9. doi: 10.1038/gt.2010.5. Epub 2010 Feb 25.

Supplemental Content

Support Center